ETH researchers have developed a new gene switch that can be activated using a commercially available nitroglycerine patch ...
T-VEC enables BCC resectability in 50% of cases, showing promise as a neoadjuvant therapy with mild side effects.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback